NCT07939399
A Study of V951A in Healthy Participants (V951A-001)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (2)
Arms and interventions
Healthy younger adult participants (typically aged 18 to 49) who will receive active injections of the investigational vaccine V951A. This group is evaluated to determine the vaccine's safety, tolerability, and early immune response in a younger population.
Healthy older adult participants (typically aged 50 and older) who will receive active injections of the investigational vaccine V951A. This group is evaluated to determine the vaccine's safety, tolerability, and early immune response in an older population.
Healthy adult participants who will receive placebo injections containing no active vaccine. This group acts as a comparator to help researchers safely evaluate the effects of the active investigational vaccine.
Biologicals: V951A
Other: Placebo